| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Aflibercept: a Potent Vascular Endothelial Growth Factor Antagonist for Neovascular Age-Related Macular Degeneration and Other Retinal Vascular Diseases
|
Sophie, Raafay
|
|
2012
|
|
1 |
p. 1-22
|
artikel
|
| 2 |
Axitinib in Metastatic Renal Cell Carcinoma
|
Mittal, Kriti
|
|
2012
|
|
1 |
p. 1-13
|
artikel
|
| 3 |
Brentuximab Vedotin in CD30+ Lymphomas
|
Perini, Guilherme Fleury
|
|
2013
|
|
1 |
p. 15-23
|
artikel
|
| 4 |
Clinical consequences of reduced dosing schedule during treatment of a patient with Pompe’s disease
|
Cortés, Emilia Barrot
|
|
2011
|
|
1 |
p. 1-6
|
artikel
|
| 5 |
Cost-Effectiveness of Infliximab for the Treatment of Acute Exacerbations of Ulcerative Colitis in the Netherlands
|
Chaudhary, Mohammad A.
|
|
2012
|
|
1 |
p. 45-60
|
artikel
|
| 6 |
Current and Novel Treatment Options for Metastatic Colorectal Cancer: Emphasis on Aflibercept
|
Dietvorst, Maria H. P.
|
|
2013
|
|
1 |
p. 25-33
|
artikel
|
| 7 |
Effect of switching recombinant human growth hormone: Comparative analysis of phase 3 clinical data
|
Romer, Tomasz
|
|
2011
|
|
1 |
p. 1-14
|
artikel
|
| 8 |
Erratum to: Human Plasma-Derived, Nanofiltered C1-Inhibitor Concentrate (Cinryze®), a Novel Therapeutic Alternative for the Management of Hereditary Angioedema Resulting From C1-Inhibitor Deficiency
|
Farkas, Henriette
|
|
2012
|
|
1 |
p. 1
|
artikel
|
| 9 |
Human Plasma-Derived, Nanofiltered, C1-Inhibitor Concentrate (Cinryze®), a Novel Therapeutic Alternative for the Management of Hereditary Angioedema Resulting from C1-Inhibitor Deficiency
|
Farkas, Henriette
|
|
2012
|
|
1 |
p. 1-17
|
artikel
|
| 10 |
Letter from the Editor
|
Yazici, Yusuf
|
|
2011
|
|
1 |
p. 1
|
artikel
|
| 11 |
New Frontiers in Subcutaneous Immunoglobulin Treatment
|
Jolles, Stephen
|
|
2011
|
|
1 |
p. 1-15
|
artikel
|
| 12 |
Pediatric Ulcerative Colitis: The Therapeutic Road to Infliximab
|
Puthoor, Pamela R.
|
|
2012
|
|
1 |
p. 1-14
|
artikel
|
| 13 |
Rotarix in Japan: Expectations and Concerns
|
Nakagomi, Osamu
|
|
2011
|
|
1 |
p. 1-13
|
artikel
|
| 14 |
Switching From Originator to Biosimilar Human Growth Hormone Using Dialogue Teamwork: Single-Center Experience From Sweden
|
Flodmark, Carl-Erik
|
|
2013
|
|
1 |
p. 35-43
|
artikel
|
| 15 |
Treatment of Systemic Juvenile Idiopathic Arthritis with Tocilizumab - the Role of Anti-Interleukin-6 Therapy After a Decade of Treatment
|
Reiff, Andreas
|
|
2012
|
|
1 |
p. 1-12
|
artikel
|
Tijdschrift beschrijving